Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 29;14(19):4751.
doi: 10.3390/cancers14194751.

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures

Ciara S McNevin  1   2 , Karen Cadoo  2   3 , Anne-Marie Baird  3 , Stephen P Finn  1 , Ray McDermott  4   5
Affiliations
Review

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures

Ciara S McNevin et al. Cancers (Basel). .

Abstract

Since 2010, significant progress has been made in the treatment of metastatic castrate resistant prostate cancer (mCRPC). While these advancements have improved survival, mCRPC remains a lethal disease, with a precision medicine framework that is lagging behind compared to other cancers. Poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) studies in prostate cancer (PCa) have focused primarily on the homologous recombination repair (HRR) genes, specifically BRCA1 and BRCA2. While homologous recombination deficiency (HRD) can be prompted by germline or somatic BRCA1/2 genetic mutations, it can also exist in tumors with intact BRCA1/BRCA2 genes. While the sensitivity of PARPi in tumors with non-BRCA DNA damage signatures is not as well established, it has been suggested that genomic alterations in DNA damage repair (DDR) genes other than BRCA may confer synthetic lethality with PARPI in mCRPC. The aim of this review is to summarize the literature on PARPi and their activity treating BRCA and non BRCA tumors with DNA damage signatures.

Keywords: BRCA; PARP inhibitors; homologous recombination repair; metastatic castrate resistant prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Repair Pathways for DSBs.
Figure 2
Figure 2
Synthetic lethality as the mechanism behind PARPi treated BRCA deficient cells leading to irreparable DNA damage.
See this image and copyright information in PMC

References

    1. Society A.C. Survival Rates for Prostate Cancer 2022. [(accessed on 15 March 2022)]. Available online: https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-stagin....
    1. ASCO.org Prostate Cancer: Statistics 2021. [(accessed on 15 March 2022)]. Available online: https://www.cancer.net/cancer-types/prostate-cancer/statistics.
    1. Carioli G., Bertuccio P., Boffetta P., Levi F., La Vecchia C., Negri E., Malvezzi M. European cancer mortality predictions for the year 2020 with a focus on prostate cancer. Ann. Oncol. 2020;31:650–658. doi: 10.1016/j.annonc.2020.02.009. - DOI - PubMed
    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Huggins C., Webster W.O. Duality of Human Prostate in Response to Estrogen. J. Urol. 1948;59:258–266. doi: 10.1016/S0022-5347(17)69373-X. - DOI - PubMed

LinkOut - more resources